Please Wait
Applying Filters...
menu
    • menu
    Athena Pharmaceutiques is a Partner of Choice for Drug Delivery & Life Cycle Management.

    Virtual Booth

    Contact Supplier

    Kikkoman Biochemifa Company advances global health and safety through precision-driven innovation in biotech and food testing.

    Virtual Booth

    Contact Supplier

    Rusan Pharma: Over 30 years of specializing in the treatment of Addiction and Pain Management.

    Virtual Booth

    Contact Supplier

    TransoPharm USA works in the Sourcing and Management of Active Pharmaceutical Ingredients.

    Virtual Booth

    Contact Supplier

    Moehs Group, a reference company in the production of pharmaceutical active ingredients.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-10-20

    Virtual Booth

    An Enquiry

    Menu

    Metopimazine Mesylate

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Neurogastrx To Present NG101 Data Reducing GLP-1 Related Nausea
    Neurogastrx To Present NG101 Data Reducing GLP-1 Related Nausea

    07 Oct 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/10/07/3162548/0/en/Neurogastrx-to-Present-Proof-of-Concept-Clinical-Data-on-Oral-Candidate-NG101-to-Reduce-Nausea-Vomiting-Associated-with-GLP-1-Agonists-at-ObesityWeek.html

    GLOBENEWSWIRE
    07 Oct 2025
    Share Share
    Neurogastrx Announces Positive Data For NG101 In Reducing Nausea
    Neurogastrx Announces Positive Data For NG101 In Reducing Nausea

    16 Oct 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/10/16/2963836/0/en/Neurogastrx-Announces-Positive-Proof-of-Concept-Data-for-Investigational-Drug-NG101-in-Reducing-Nausea-and-Vomiting-Associated-with-the-Administration-of-GLP-1-Agonist-Medication.html

    GLOBENEWSWIRE
    16 Oct 2024
    Share Share